Compare KLAR & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLAR | KRYS |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 7.8B |
| IPO Year | N/A | 2017 |
| Metric | KLAR | KRYS |
|---|---|---|
| Price | $14.96 | $249.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $39.57 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 8.7M | 260.2K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 6.84 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $28.95 | $40.88 |
| Revenue Next Year | $20.22 | $35.16 |
| P/E Ratio | ★ N/A | $36.15 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $12.50 | $123.03 |
| 52 Week High | $47.48 | $298.30 |
| Indicator | KLAR | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 39.69 |
| Support Level | $12.50 | $233.64 |
| Resistance Level | $32.70 | $293.60 |
| Average True Range (ATR) | 1.09 | 9.00 |
| MACD | 0.64 | -2.10 |
| Stochastic Oscillator | 56.27 | 14.28 |
Klarna is the largest pure-play in the buy now, pay later space. The company operates a two-sided network with a payment method at its core, but it is ultimately a lender. Merchants sign up with Klarna to increase turnover in their stores. Primarily, Klarna can provide merchants with higher conversion rates and average order values relative to other payment methods. Some merchants enter a symbiotic relationship with Klarna, advertising its brand on the product page to drive conversion and to benefit from Klarna's brand value in the merchant's sales funnel. Customers use Klarna for its ease of use, quick access to credit, zero-interest financing, and lower reminder fees.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.